Publications
Detailed Information
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su-Jung | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2012-06-27T07:08:18Z | - |
dc.date.available | 2012-06-27T07:08:18Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2010-08-23 | - |
dc.identifier.citation | BMC Cancer, Vol.10, p. 448 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 95273 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77622 | - |
dc.description.abstract | Background: Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent neuroendocrine tumor (NET) have been few. Methods: We enrolled patients with metastatic/recurrent NET diagnosed between January 1996 and July 2007 and retrospectively analyzed. Results: A total of 103 patients were evaluated. Twenty-six patients (25.2%) had pancreatic NET, 27 (26.2%) had gastrointestinal NET, 2 (1.9%) had lung NET, 28 (27.2%) had NET from other sites, and 20 (19.4%) had NET from unknown origin. The liver was the most common metastatic site (68.9%). Thirty-four patients had grade 1 disease, 1 (1.0%) had grade 2 disease, 15 (14.6%) had grade 3 disease, 9 (8.7%) had large cell disease, and 7 (6.8%) had small cell disease. Sixty-six patients received systemic treatment (interferon, somatostatin analogues or chemotherapy), 64 patients received local treatment (TACE, radiofrequency ablation, metastasectomy, etc.). Thirty-six patients received both systemic and local treatments. Median overall survival (OS) was 29.0 months (95% confidence interval, 25.0-33.0) in the 103 patients. OS was significantly influenced by grade (p = .001). OS was 43.0, 23.0, and 29.0 months in patients who received local treatment only, systemic treatment only, and both treatments, respectively (p = .245). The median time-to-progression (TTP) was 6.0 months. Overall response rate was 34.0% and disease-control rate was 64.2%. TTP was influenced by the presence of liver metastasis (p = .011). Conclusions: OS of metastatic/recurrent NET was different according to tumor grade. TTP was different according to metastasis site. Therefore, development of optimal treatment strategy based on the characteristics of NET is warranted. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | - |
dc.title | Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/1471-2407-10-448 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.description.citedreference | Hill JS, 2009, CANCER, V115, P741, DOI 10.1002/cncr.24065 | - |
dc.description.citedreference | Gurusamy KS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007060.pub2 | - |
dc.description.citedreference | IGAWA S, 2009, LUNG CANCER, V68, P438 | - |
dc.description.citedreference | DAHAN L, 2009, ENDOCR RELAT CANC | - |
dc.description.citedreference | RINKE A, 2009, J CLIN ONCOL | - |
dc.description.citedreference | Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858 | - |
dc.description.citedreference | Kulke MH, 2008, J CLIN ONCOL, V26, P3403, DOI 10.1200/JCO.2007.15.9020 | - |
dc.description.citedreference | Cho CS, 2008, CANCER, V113, P126, DOI 10.1002/cncr.23523 | - |
dc.description.citedreference | Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377 | - |
dc.description.citedreference | Kwekkeboom DJ, 2008, J CLIN ONCOL, V26, P2124, DOI 10.1200/JCO.2007.15.2553 | - |
dc.description.citedreference | Bettini R, 2008, ANN ONCOL, V19, P903, DOI 10.1093/annonc/mdm552 | - |
dc.description.citedreference | Vilar E, 2007, ENDOCR-RELAT CANCER, V14, P221, DOI 10.1677/ERG-06-0074 | - |
dc.description.citedreference | Ekeblad S, 2007, CLIN CANCER RES, V13, P2986, DOI 10.1158/1078-0432.CCR-06-2053 | - |
dc.description.citedreference | Bajetta E, 2007, CANCER CHEMOTH PHARM, V59, P637, DOI 10.1007/s00280-006-0306-6 | - |
dc.description.citedreference | Hainsworth JD, 2006, J CLIN ONCOL, V24, P3548, DOI 10.1200/JCO.2005.05.0575 | - |
dc.description.citedreference | Pavel ME, 2006, J INTERF CYTOK RES, V26, P8 | - |
dc.description.citedreference | Tomassetti P, 2005, ANN ONCOL, V16, P1806, DOI 10.1093/annonc/mdi358 | - |
dc.description.citedreference | Rorstad O, 2005, J SURG ONCOL, V89, P151, DOI 10.1002/jso.20179 | - |
dc.description.citedreference | Wirth LJ, 2004, LUNG CANCER-J IASLC, V44, P213, DOI 10.1016/j.lungcan.2003.11.016 | - |
dc.description.citedreference | Faiss S, 2003, J CLIN ONCOL, V21, P2689, DOI 10.1200/JCO.2003.12.142 | - |
dc.description.citedreference | Virgolini I, 2002, SEMIN NUCL MED, V32, P148, DOI 10.1053/snuc.2002.31565 | - |
dc.description.citedreference | Kaltsas G, 2001, CLIN ENDOCRINOL, V55, P575 | - |
dc.description.citedreference | Fjallskog MLH, 2001, CANCER, V92, P1101 | - |
dc.description.citedreference | Johanson V, 1999, BRIT J CANCER, V80, P1259 | - |
dc.description.citedreference | MOERTEL CG, 1992, NEW ENGL J MED, V326, P519 | - |
dc.description.citedreference | RIDOLFI R, 1991, J CHEMOTHERAPY, V3, P328 | - |
dc.description.citedreference | MOERTEL CG, 1991, CANCER, V68, P227 | - |
dc.description.citedreference | OBERG K, 1983, NEW ENGL J MED, V309, P129 | - |
dc.description.citedreference | MOERTEL CG, 1980, NEW ENGL J MED, V303, P1189 | - |
dc.description.citedreference | RANSOM WB, 1890, LANCET, V2, P1020 | - |
dc.description.tc | 0 | - |
dc.identifier.wosid | 000282717900002 | - |
dc.identifier.scopusid | 2-s2.0-77955834798 | - |
dc.citation.startpage | 448 | - |
dc.citation.volume | 10 | - |
dc.identifier.sci | 000282717900002 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CARCINOID-TUMORS | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ETOPOSIDE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | STREPTOZOCIN | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | MIDGUT | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.